source
- STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and moreNovartis is largely abandoning a drug once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and deathsSTAT · 2h ago↗ source
- J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depressionDelix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase 2-ready non-hallucinatory psychedelic therapy for depression.Fierce Biotech · 7h ago↗ source
- Recent heart-drug trials miss endpoints, raising doubts about AI-driven drug designTwo large clinical studies presented at the American Heart Association meeting this weekend failed to show any benefit for experimental heart‑attack and stroke therapies, underscoring the difficult…